Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer

Inclusion Criteria:

1. Patients with advanced malignancies, either refractory to standard therapy or for
which no effective standard therapy is available, unless the drugs in the protocol are
part of the standard of care for a specific diagnosis.Predominant hepatic metastasis
is defined as at least 50% of the total tumor burden involving the liver. For patients
who are enrolled into the arm of mFOLFOX6 plus Bevacizumab, they must have metastatic
colorectal cancer with predominant hepatic metastases.For patients who are enrolled
into the arm of DAT, they must have predominant hepatic metastases harboring an
aberrant PI3K pathway detected in a CLIA-certified laboratory.

2. Patients must have measurable or evaluable disease, as defined by RECIST 1.1.

3. Men or women aged greater or equal than18 years

4. Women of child-bearing potential (women who are not postmenopausal for at least one
year or are not surgically sterile) and men must agree to use adequate contraception
(e.g., hormonal, barrier device, or abstinence) prior to study entry, for the duration
of study participation, and for 30 days after the last dose the study agents.

5. Patients must have an ECOG performance status of 0 to 2.

6. Patients must have adequate organ functions as defined below: Neutrophils greater or
equal than 1,500 /microliter. Platelets greater or equal than 100,000 /microliter.
Total bilirubin smaller or equal than 1.5 x ULN (upper limit of normal) (except
patients with Gilbert's syndrome, who must have a total bilirubin smaller or equal
than 3.0 mg/dL). ALT smaller or equal than 3 x ULN or smaller or equal than 5 x ULN if
liver metastases persist. Serum creatinine smaller or equal than 1.5 mg/dL or
calculated creatinine clearance greater or equal than 50 mL/minutes

7. Patients should be able to read and fully understand the requirements of the trial, be
willing to comply with all trial visits and assessments, and be willing and able to
sign an IRB-approved written informed consent document.

8. Patients may receive palliative radiation therapy immediately before or during the
treatment if the radiation therapy is not delivered to the sole target lesions.

Exclusion Criteria:

1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection requiring intravenous antibiotics, symptomatic congestive heart failure
(NYHA Class III or IV), unstable angina pectoris, uncontrolled systemic hypertension
(systolic BP > 140 mm Hg, diastolic BP > 90 mm Hg), left ventricular ejection fraction
< 50%, active bleeding, or psychiatric illness/social situations that would limit
compliance with study requirements.

2. Patients who have not recovered from major surgical procedure, or significant
traumatic injury (i.e., patients still need additional medical care for these issues).

3. History of allergic reactions to the study drugs or their analogs, or any component of
the products, or sensitive to conductive hydrogels used on electrocardiogram (ECG)
stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.

4. Any treatment specific for tumor control within 3 weeks of drugs; or within 2 weeks if
cytotoxic agents were given weekly (within 6 weeks for nitrosoureas or mitomycin C),
or within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects
lasting fewer than 4 days (that includes, but is not limited to, erlotinib, sorafenib,
sunitinib, bortezomib, and similar agents), or failure to recover from the toxic
effect of any of these therapies prior to study entry.

5. Symptomatic primary tumors or metastasis of brain and/or central nervous system that
are uncontrolled with antiepileptics and requiring high doses of steroids.

6. Implanted pacemaker, defibrillator, nerve stimulator or other active electronic
medical devices.

7. QTc is greater than 480 milliseconds (msec) at screening, or documented clinically
significant arrhythmias. The QTc formula Bazett will be used for assessing subject
eligibility.

8. History of stroke or transient ischemic attack, peripheral vascular disease, active
gastric or duodenal ulcer, abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess within 6 months prior to study enrollment.

9. Patients with known human immunodeficiency virus infection, active hepatitis B or C.

10. Women who are pregnant will be excluded from the study.